Myo-inositol supplement in pregnant people with obesity to help prevent gestational diabetes
Tests myo-inositol versus placebo in pregnant people with obesity, using glucose monitoring.
Plain-language title generated from the registry record
Registry title: Myo-inositol During Pregnancy to Prevent Gestational Diabetes
Key facts
- Where
- Boston, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with obesity who are expecting one baby. It tests whether myo-inositol or a placebo is taken during pregnancy.
- Age
- Over 18 years and under 45 years
- Sex
- Women only
- Disease stage
- Pregnant with one baby (singleton), recruited before 16 weeks of pregnancy, with a pre-pregnancy BMI of 30 or more (obese).
- Earlier treatment
- People taking medicines that affect body weight or metabolism (for example metformin) cannot join.
Main reasons for not taking part
- Pregnant with more than one baby
- Diabetes before the pregnancy
- Taking medicines that affect body weight or metabolism, such as metformin
- Cannot tolerate a glucose tolerance test
- Adults unable to give consent
This trial only enrols pregnant participants. The registry sentence this rests on: Recruited before 16 weeks gestation
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT06575868, who can take part
Where in United States
- Tufts Medical CenterBoston, United StatesContact: Zeunab KassemTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tufts Medical Center
- Trial code
- NCT06575868
- Record updated
- 29 April 2025
- Original description
Myoinositol is an insulin-like compound that is present in both plant and animal cells. Humans synthesize it naturally, but it is also obtained in our diet. It works through an intracellular signaling pathway to increase insulin sensitivity. Myoinositol has been used as an over-the-counter (OTC) supplement in the management of polycystic ovarian syndrome due to this effect. Myoinositol has also been shown to improve glycemic profiles in pregnant euglycemic women and well as improve insulin sensitivity in pregnant patients with gestational diabetes mellitus (GDM).Read full original descriptionShow less
Continuous Glucose Monitoring in Myo-inositol Supplemented Obese Pregnant Individuals: a Feasibility Pilot Randomized Control Trial
Myoinositol is an insulin-like compound that is present in both plant and animal cells. Humans synthesize it naturally, but it is also obtained in our diet. It works through an intracellular signaling pathway to increase insulin sensitivity. Myoinositol has been used as an over-the-counter (OTC) supplement in the management of polycystic ovarian syndrome due to this effect. Myoinositol has also been shown to improve glycemic profiles in pregnant euglycemic women and well as improve insulin sensitivity in pregnant patients with gestational diabetes mellitus (GDM).
This is a double blind RCT offering myo-inositol or placebo to those who are eligible and enrolled.
Inclusion: Singleton gestations; Women aged > 18 years and < 45 years; Recruited before 16 weeks gestation; Obese (pre-pregnancy BMI ≥ 30); Receiving prenatal care at Tufts Medical Center; Planning to give birth at Tufts Medical Center; Can tolerate glucose tolerance test; Willing and able to wear CGM; Willing and able to sign informed consent.
Exclusion: Taking medications that impact body weight or metabolism (eg metformin); Preexisting diabetes; Inability to tolerate glucose tolerance test; Multiple gestation; Adults unable to consent (cognitively impaired adults); Wards of the state; Non-viable neonates; Neonates of uncertain viability.